{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000395","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.986674+00:00","generated_at":"2026-06-20T17:54:22.650891+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kezar Life Sciences reports preliminary cash of $276.6M and 68.5M shares outstanding as of Dec 31, 2022","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$276.6M as of Dec 31, 2022.","Approximately 68.5 million shares of common stock outstanding as of year-end 2022.","Estimates are unaudited and subject to change upon completion of year-end closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000395","json":"https://secwatch.observer/filing/0000950170-23-000395.json","markdown":"https://secwatch.observer/filing/0000950170-23-000395.md","text":"https://secwatch.observer/filing/0000950170-23-000395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023000395/0000950170-23-000395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023000395/kzr-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:54:22.650891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}